FibroBiologics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-16.
FibroBiologics, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 16, 2026. FibroBiologics, Inc. trades on Nasdaq as FBLG. The filing reports $500K sold. Its industry group is Pharmaceuticals. It names Pete O'Heeron (Chief Executive Officer), Richard Cilento (Director), Robert Hoffman (Director) (SEC Form D, September 16, 2026).
FibroBiologics, Inc. raised on Sep 16. 125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to FibroBiologics, Inc.? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like FibroBiologics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-16 · the record
Pitching, partnering or investing alongside them? See who really runs and owns FibroBiologics, Inc.
Free to see. No signup.
More on the people and the money behind FibroBiologics, Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when FibroBiologics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when FibroBiologics, Inc. raises, hires or launches. No email unless you switch it on.
Watch FibroBiologics, Inc. →Get the full cited report on FibroBiologics, Inc.
What the filing shows about FibroBiologics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on FibroBiologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives FibroBiologics, Inc.'s address as 9350 Kirby Drive, Suite 300, Houston, TX 77054.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for FibroBiologics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
FibroBiologics, Inc. is a registered filer with the SEC (CIK 1958777) and has filed since 2025-12-03. 6 filings are on record, the latest on 2026-10-13.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
FibroBiologics, Inc.'s Form D of 2026-09-16 names Pete O'Heeron, Richard Cilento, Robert Hoffman and 6 more as its officers, directors or promoters.
Its new offerings report $11.93M sold across 6 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $500K, on the same scale — one filing against the whole group's total, so it sits low by construction.
The issuer intends to use the net proceeds from this offering for working capital and general corporate purposes.
Checked away from the filing. What is below does not come from the record on sec.gov.
FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and…
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer, Director.
Pete O'Heeron is named as Chief Executive Officer on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Richard Cilento is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Robert Hoffman is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Victoria Niklas is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Kathleen Rubins is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Leigh Steinberg is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Jason Davis is named as Chief Financial Officer on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Ruben Garcia is named as General Counsel on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Hamid Khoja is named as Chief Scientific Officer on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
9 people named on the filing — 4 holding an executive role and 5 as directors only.
Named as of the 2026-09-16 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about FibroBiologics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on FibroBiologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on FibroBiologics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist FibroBiologics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind FibroBiologics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-25 (ir.fibrobiologics.com).
Each opens in a new tab, filled in for FibroBiologics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Houston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/fibrobiologics-inc-form-d-042792